Profile: TorriSalaman

Your personal background.
—After nearly two decades of helping men with erectile
dysfunction (ED) treat their condition, Pfizer continues its commitment to these patients with a single dose VIAGRA package.
This is the first of its kind packaging of any FDA approved ED treatment and is similar in size to the
packaging pouch used for single dose ADVIL. In 2014, an average of
500,000 men used VIAGRA each month according to IMS data.
About half of men over 40 have some degree of ED, according to a study published in the Journal of Urology, known as the Massachusetts Male Aging Study.

The study found that of 1,290 respondents, 52 percent stated that they had some degree
of ED.2 The launch of VIAGRA Single Packs offers another
option for men to take VIAGRA with them when they need it.
VIAGRA usually starts to work within 30-60 minutes.


youtube.com[url=http://onlineedshop.com/?wm=2309 flushing; upset stomach; abnormal vision, such as changes in color vision (such as having a blue color tinge) and blurred vision; stuffy or runny nose; back pain; muscle pain; nausea; dizziness; rash. VIAGRA (sildenafil citrate) is prescription medicine used to treat erectile dysfunction (ED). VIAGRA is not for women or children. You are encouraged to report negative side effects of prescription drugs to the FDA. Patients should always ask their doctors for medical advice about adverse events. Food and Drug Administration (FDA) directly. The FDA has established a reporting service known as MedWatch where healthcare professionals and consumers can report serious problems they suspect may be associated with the drugs and medical devices they prescribe, dispense, or use. 2Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Breakthrough} Impotence Cure - and its medical and psychosocial correlates:
results of the Massachusetts Male Aging Study.



The Group’s nutraceuticals division, Entity Health Limited, recently
launched its Entity line of nutraceutical products and
is engaged in the development and commercialisation of nutraceutical products
that address specific conditions and improve quality of life.

In addition to the successful registration of SILCAP and WAFESIL on the Australian Register of Therapeutic Goods ("ARTG"), the Group’s nutraceutical arm, Entity Health, has also
applied for assessment by TGA for quality and safety of its nutraceutical products.
To-date, the Group has successfully obtained 15 product listings on the ARTG with 8 listings for domestic sales and 7 listings for export sales on the
ARTG.


Many people associate erectile dysfunction with the silver-haired men in Viagra commercials.
Yet Zachariah Reitano was just 17 years old when he experienced it
for the first time. Confused and frustrated, he knew something was
wrong. He was right. It's well established among doctors that erectile dysfunction can be the first sign of a more troubling health
problem, especially in younger men. Unfortunately, many men ignore that sign because of the embarrassment and stigma
that surround the condition, he says, and doctors often don't raise
the subject during checkups. Reitano's experience led him to start the men's-health company
Roman, which prescribes and delivers medications like Viagra and its lower-cost generic, called sildenafil.



Roman is one of a slew of new companies like Hims and others shaking up the traditional
model of healthcare by offering this kind of online service targeted specifically at erectile dysfunction. These new companies
paint erectile dysfunction as a problem among younger, not-yet-graying men, but one for which there is
help. It raises two important questions: How can these online companies care
for patients who could have serious underlying health conditions like
Reitano? And are these companies overhyping how common erectile dysfunction is
in younger men? 1 billion valuation. But a move to relax
guidelines has raised concerns among some of its doctor partners.
But Roman and its telemedicine peers say they can direct patients
to get appropriate care, even if it's not through their own companies.

They also say they're combating the stigma associated with impotence by talking about the condition openly and making care accessible in a discrete, affordable way.



The study, "Nintedanib plus Sildenafil in Patients with Idiopathic Pulmonary Fibrosis," was published in the The New England Journal of Medicine.
Although treatment with sildenafil did not improve exercise tolerance (measured by the six-minute walk test) compared to placebo,
it did lead to small but significant improvements in blood oxygenation, DLCO,
and quality of life in these patients. Interested
in Pulmonary Fibrosis research? Sign up to our forums and join the conversation! Patients were randomly
assigned to receive either Ofev 150 mg twice daily plus sildenafil 20 mg three times daily, or Ofev 150 mg twice daily plus placebo three times daily
for 24 weeks. The primary endpoint of the trial was a change in health-related quality of life, assessed by
the St. George’s Respiratory Questionnaire (SGRQ.
A higher score indicates a better health-related quality of
life. Secondary endpoints included measures of
dyspnea (shortness of breath) and safety. No significant differences
were seen between the combo therapy or Ofev alone in terms of health-related quality
of life at week 12 or week 24 after treatment. Forced vital capacity (FVC), however, which refers to the volume of air in liters the lungs can sustain,
tended to decline more slowly in the Ofev plus sildenafil group
than in the Ofev group. A total of 25.5% of patients receiving the Ofev
plus sildenafil combo had a relative decline of at least 10% of the
predicted FVC value or died, CHECK OUT * Breakthrough Cure For Erectile Dysfunction : Best
Prices
compared with 36.8% in the Ofev group.


To predict the impact of the DSM-5's take on sexual dysfunction, researchers
analyzed data from sexually active respondents to Britain's Third National Survey of Sexual Attitudes and Lifestyles (Natsal-3).

11,509 male and female participants aged 16 to 74, reporting at least one sexual partner in the
past year, responded to questions about sexual function problems.
Among sexually active men, the prevalence of reporting one
or more of four specific sexual problems was 38.2%, but only 4.2% met the DSM-5 duration, severity, and distress criteria.
More information: Kirstin R. Mitchell et al.
Provided by Taylor 5.6 percent in men aged 50-59; 17
percent in men aged 60-69 and 38.8 percent in men 70 years
and older. Those initial data and the increasing incidence of
erectile dysfunction over time were linked to data from a long-term study of heart disease in Olmsted County residents, led by Veronique Roger, M.D., Mayo Clinic cardiologist.
Over 10 years of follow-up, researchers found that men with
erectile dysfunction were 80 percent more likely to develop coronary heart disease compared to men without erectile dysfunction. The highest
risk of new heart disease was seen in the youngest study participants who had erectile dysfunction.


In men 40 to 49 years old when the study began, the
number of new cases in men with erectile dysfunction was more than 50-fold higher than in men without erectile
dysfunction. In men in their 50s, 60s and 70s, the total incidence of new cases of
heart disease also was higher in those with erectile dysfunction. However, the differences
were not as striking as those seen among the 40- to 49-year- olds.
This study did not determine reasons for the increased risk of heart disease among
men with erectile dysfunction. Some have theorized that erectile
dysfunction and coronary artery disease may be different manifestations of the same underlying
disease process. A buildup of plaque that can block arteries around
the heart may plug the smaller penile arteries first, causing erectile dysfunction. Alternatively,
arteries may lose elasticity over time, contributing to
heart disease. This arterial stiffening may affect the smaller penile arteries first.




Male bowel cancer patients are very likely to suffer from erectile dysfunction (ED) after treatment
and yet the majority are not receiving adequate
information about the condition, according to a study published in the British Medical Journal today.
Bowel cancer affects over
38,000 people every year in the UK with around half of patients surviving for more than five years after treatment.
This figure is set to increase, says the study.
Men are more likely to develop bowel cancer and many will suffer from
ED after their treatment, say the authors, led by Professor Sue Wilson at
the University of Birmingham. The research team carried out a series of in-depth interviews with 28 patients in the West Midlands
who had been treated for bowel cancer. Most of the respondents
experienced ED as a result of their treatment.
Yet many had been uninformed and unprepared
for it. Almost none were receiving adequate, effective and affordable care for the condition.


In the August issue of Mayo Clinic Proceedings,
researchers from Utah and several colleagues compare the relative safety of two systems -- an online prescribing service versus traditional
physician consultation -- for patients seeking medication to treat erectile dysfunction. Online prescribing, also
called e-medicine prescribing, is relatively new in the United States.

International Index of Erectile Questions (IIEQs) and
the level of patient education provided by prescribers.
One area the e-medicine system appeared to
excel was patient education. The authors noted that 100 percent of the e-medicine clients received written manufacturer product information, and 75.2 percent of e-medicine clients received tailored electronic messages.
In comparison, study data showed that no medication instructions were recorded for 51.8 percent of patients who
received prescriptions via a traditional physician consultation. The researchers acknowledge that additional
research is needed to confirm these results. This document is subject to copyright.
Apart from any fair dealing for the purpose of private study or research,
no part may be reproduced without the written permission. The content is provided for information purposes only.



If you pop an erectile dysfunction pill, there are a couple of things you expect to happen. Your vision turning permanently red probably isn’t
one of them. After a 31-year-old man took liquid
sildenafil citrate—the active ingredient in most ED drugs, including Viagra and Check this link out
~ Brilliant Treatment For Impotence >>>Quantities Limited

Cialis—his vision took on a red tint. Two
days later he went to the emergency room and doctors diagnosed him
with retinal toxicity, confirming the drug had caused actual structural changes to his retina.
Interestingly, it’s the active ingredient in ED meds that helps a
guy get it up—a compound called phosphodiesterase-5 (PDE-5) inhibitor—that can also impair your vision.
"Normally, the effect of ED drugs on PDE-5 in the corpora cavernosa is at least 10 times stronger than the effect on PDE-6 in the retina, so there is no problem," explains Kulkarni.



* My 2019 Solution website ::
Find your cure here >>>Brilliant Treatment For Erectile Dysfunction >My 2019 Solution
Your feedback on this profile
Recommend this profile for User of the Day: I like this profile
Alert administrators to an offensive profile: I do not like this profile
Account data View
Team None


©2020 Progger & Stefano Tognon (ice00)